Literature DB >> 15201573

Weight gain during long-term treatment with olanzapine: a case series.

Egon Michael Haberfellner1, Hans Rittmannsberger.   

Abstract

The aim of this study was to assess the prevalence of weight gain during long-term treatment with olanzapine under routine conditions. Weight changes in a sample of 27 outpatients with schizophrenic or schizoaffective disorder were assessed over a mean duration of treatment of 22 months (6-42 months). Treatment with olanzapine was started anew or switched from a conventional antipsychotic drug. Eighteen (66.7%) patients gained more than 7% of their initial body weight. Mean weight gain was 9.2 kg over the study period for the first year 7.7 kg, and only 1.7 kg in the second year. Due to some patients losing weight in the second year, the latter finding obscures the fact that more than 50% of patients gained considerable weight also during the second year (4.8 kg). Weight gain per month was significantly higher in patients with lower body mass index, yet the highest weight gain was found in the most obese patient. Weight gain under olanzapine is a serious concern, and should be monitored closely and countered by active measures.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15201573     DOI: 10.1097/01.yic.0000113105.67404.5f

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  4 in total

1.  Body mass index and weight gain as alternative or complementary hypothesis to explain olanzapine concentration-dose ratio accumulation.

Authors:  Bruno Charpiat
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

Review 2.  Long-term treatment with atypical antipsychotics and the risk of weight gain : a literature analysis.

Authors:  Salvatore Gentile
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

3.  Relationship between insight, cognitive function, social function and symptomatology in schizophrenia: the West London first episode study.

Authors:  Stanley H Mutsatsa; Eileen M Joyce; Sam B Hutton; Thomas R E Barnes
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-08-04       Impact factor: 5.270

4.  Evaluation of the efficacy and safety of olanzapine as an adjunctive treatment for anorexia nervosa in adolescent females: a randomized, double-blind, placebo-controlled trial.

Authors:  Wendy Spettigue; Annick Buchholz; Katherine Henderson; Stephen Feder; David Moher; Kader Kourad; Isabelle Gaboury; Mark Norris; Sheila Ledoux
Journal:  BMC Pediatr       Date:  2008-01-31       Impact factor: 2.125

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.